# NPR

Type: organization

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/npr-organization
Canonical HTML page: https://getbiobrief.com/entity/npr-organization

## Timeline

- **2026-Q4 (expected)**: First Approvals — Anticipated first wave of gene therapy approvals under the new streamlined framework.
- **2026-02-23**: Framework Formalized — FDA officially announces the 'plausible mechanism' framework for ultra-rare disease therapies.
- **2025-11-15**: Draft Guidance Issued — FDA releases draft guidance on using surrogate endpoints for gene therapy accelerated approval.
- **2023-09-29**: START Pilot Launch — FDA launches the Support for clinical Trials Advancing Rare disease Therapeutics (START) pilot program.

## Recent coverage (1 stories)

### FDA Accelerates Gene Therapy Approvals via 'Plausible Mechanism' Framework
2026-02-23 22:39:41 · Sentiment: Bullish · Impact: 8/10 · Sources: 8

The FDA has officially introduced a streamlined regulatory pathway for gene therapies, allowing for accelerated approval based on 'plausible mechanisms' and biomarkers rather than traditional clinical outcomes. This landmark shift aims to fast-track treatments for ultra-rare diseases where traditional large-scale clinical trials are statistically impossible.
Full story: https://getbiobrief.com/story/fda-quicker-path-gene-therapies-accelerated-approval

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.